We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
7.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX icon
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EWTX icon
1
Edgewise Therapeutics
EWTX
$4.01B
$631M 11.68%
15,518,492
– –
2021 Q1
21 quarters
ELVN icon
2
Enliven Therapeutics
ELVN
$2.92B
$344M 6.37%
6,776,632
-1,182,906
-15% -$50.2M
2020 Q1
25 quarters
LLY icon
3
Eli Lilly
LLY
$1.04T
$309M 5.73%
257,900
+21,100
+9% +$21.6M
2023 Q1
13 quarters
MBX icon
4
MBX Biosciences
MBX
$2.42B
$189M 3.51%
3,428,736
-209,151
-6% -$7.3M
2024 Q3
7 quarters
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$184M 3.42%
2,718,735
– –
2022 Q2
16 quarters
AZN icon
6
AstraZeneca
AZN
$243B
$171M 3.17%
915,700
+245,500
+37% +$46.2M
2026 Q1
1 quarter
GPCR icon
7
Structure Therapeutics
GPCR
$1.61B
$119M 2.2%
2,209,400
+733,997
+50% +$32.5M
2024 Q2
8 quarters
SION icon
8
Sionna Therapeutics
SION
$201M
$112M 2.08%
2,555,877
-974,825
-28% -$39M
2025 Q1
5 quarters
CRVS icon
9
Corvus Pharmaceuticals
CRVS
$795M
$107M 1.98%
7,165,006
– –
2016 Q1
41 quarters
AVBP icon
10
ArriVent BioPharma
AVBP
$806M
$105M 1.95%
3,027,328
– –
2024 Q1
9 quarters
GH icon
11
Guardant Health
GH
$21.9B
$87.6M 1.62%
583,700
+148,500
+34% +$16.2M
2026 Q1
1 quarter
ARGX icon
12
argenx
ARGX
$50.5B
$86.2M 1.6%
92,880
-44,020
-32% -$36.3M
2022 Q1
17 quarters
MRK icon
13
Merck
MRK
$353B
$85.2M 1.58%
663,400
– –
2026 Q1
1 quarter
QURE icon
14
uniQure
QURE
$1.47B
$83.3M 1.54%
1,807,486
-328,663
-15% -$8.6M
2025 Q3
3 quarters
PRAX icon
15
Praxis Precision Medicines
PRAX
$6.81B
$77M 1.43%
230,100
+57,600
+33% +$18.2M
2025 Q4
2 quarters
EW icon
16
Edwards Lifesciences
EW
$49.5B
$75.5M 1.4%
834,900
-395,700
-32% -$33.1M
2024 Q4
6 quarters
PRLD icon
17
Prelude Therapeutics
PRLD
$283M
$73.2M 1.36%
13,724,571
+2,815,315
+26% +$12.3M
2020 Q3
23 quarters
ABVX icon
18
Abivax
ABVX
$7.4B
$72.8M 1.35%
546,522
+80,822
+17% +$9.15M
2025 Q3
3 quarters
DYN icon
19
Dyne Therapeutics
DYN
$2.88B
$71.9M 1.33%
3,235,684
+317,800
+11% +$5.91M
2024 Q1
9 quarters
NTRA icon
20
Natera
NTRA
$57B
$71.1M 1.32%
262,000
– –
2015 Q3
43 quarters
CGON icon
21
CG Oncology
CGON
$5.53B
$69.1M 1.28%
972,800
+24,533
+3% +$1.6M
2024 Q3
7 quarters
UNH icon
22
UnitedHealth
UNH
$340B
$67M 1.24%
+161,100
New +$59.7M
2026 Q2
0 quarters
SPRY icon
23
ARS Pharmaceuticals
SPRY
$402M
$66.4M 1.23%
8,288,510
– –
2020 Q4
22 quarters
ASND icon
24
Ascendis Pharma A/S
ASND
$14.7B
$65.2M 1.21%
244,456
+62,479
+34% +$14.6M
2025 Q2
4 quarters
HUM icon
25
Humana
HUM
$51.1B
$65.2M 1.21%
+164,100
New +$46.7M
2026 Q2
0 quarters
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.